Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Notable: Effects and Safety of CT-P51 and Keytruda · Previously Untreated Metastatic Lung Cancer Primary endpoint(s) modified CelltrionPhase 3 NCT06939595
  2. Notable: Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis Results posted: Nov 19, 2026 Bausch Health Americas, Inc.Phase 3 NCT05071716
  3. Notable: Outcomes of Efgartigimod PH20 SC · New-onset Generalized Myasthenia Gravis (gMG) Primary endpoint(s) modified argenxPhase 4 NCT06909214
  4. Notable: SOA101 · Advanced Solid Tumors Primary endpoint(s) modified Shine-On Biomedical Co., Ltd.Phase 1/2 NCT07055594
  5. Notable: NEROFE, a Novel Hormone-Peptide · Advanced MDS and AML Primary completion pushed from Jun 30, 2025 to Dec 31, 2027 Immune System Key LtdPhase 1 NCT04365179
  6. Notable: External Electrical Stimulation for Male Incontinence Results posted: Nov 19, 2026 Elidah, Inc.Not applicable NCT06620419
  7. Notable: Simple-Prep Controlled Embolic Results posted: Nov 19, 2026 Fluidx Medical Technology, Inc.Not applicable NCT06453642
  8. Notable: Nutrition and Swelling Primary endpoint(s) modified University of California, San FranciscoPhase 2 NCT07899762
  9. Notable: SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept · Newly Diagnosed Pulmonary Arterial Hypertension Primary endpoint(s) modified Philipps University MarburgPhase 2 NCT07266519
  10. Notable: Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy · Advanced Non-small Cell Lung Cancer Primary completion pushed from Aug 31, 2025 to Oct 31, 2028 Second Xiangya Hospital of Central South UniversityPhase 1/2 NCT05979818
  11. Notable: Vinpocetine in Healthy Volunteers Primary and study completion pushed from Jun 1, 2026 to Dec 31, 2026 Stanford UniversityPhase 1 NCT06635746
  12. Notable: Talazoparib + Tazemetostat for mCRPC Results posted: Nov 19, 2026 Dana-Farber Cancer InstitutePhase 1 NCT04846478
  13. Notable: Building Healthy Food Environment in Schools: Evaluating Co-created Interventions in Low Resource Settings. #BetterNutrition4Adolescent Enrollment increased: 2600 → 4464 participants Norwegian University of Science and TechnologyNot applicable NCT07332676
  14. Notable: Automated, Assistive, Non-Contact Sleep Quality Monitor for Older Adults Recruitment opened Indiana UniversityNot applicable NCT06045988
  15. Notable: BFR and Neuromuscular Training in Knee Osteoarthritis (KOA) Primary endpoint(s) modified University of LahoreNot applicable NCT07942883
  16. Notable: Screen Time Exposure and Behavioral Outcomes Primary endpoint(s) modified Sohag UniversityNot specified NCT07941596
  17. Notable: Cost-Effectiveness of the Healthy Beat Acupunch Regimen in Community-Dwelling Older Adults Primary endpoint(s) modified Mahidol UniversityNot applicable NCT07868575
  18. Notable: Perianchor Cyst Formation, Tendon Healing, and Clinical Outcomes Following Arthroscopic Rotator Cuff Repair Primary endpoint(s) modified Fatih Sultan Mehmet Training and Research HospitalNot specified NCT07661680
  19. Notable: Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache) Recruitment opened Universität Duisburg-EssenNot applicable NCT07729059
  20. Notable: Empowered Relief for Caregivers Recruitment opened Stanford UniversityNot applicable NCT07636980
  21. Notable: SHOFU FX-LC RMGI Restoration Versus FUJI II RGMI · Anterior Carious Cervical Lesions Enrollment increased: 36 → 56 participants Cairo UniversityNot applicable NCT07937176
  22. Notable: Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients Primary endpoint(s) modified Swiss Cancer InstituteNot applicable NCT06114108
  23. Notable: Validation of AR Based Neuronavigation System Recruitment opened Seoul National University HospitalNot applicable NCT05776706
  24. Notable: Paclitaxel Polymeric Micelles for Injection · Metastatic Breast Cancer Primary completion pushed from Dec 2025 to Dec 31, 2027 Shanghai Yizhong Pharmaceutical Co., Ltd.Phase 3 NCT06143553
  25. Notable: Pacritinib · VEXAS Syndrome (PAXIS) Primary completion pushed from Dec 30, 2026 to Oct 30, 2028 Swedish Orphan BiovitrumPhase 2 NCT06782373